Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

12.0%

3 terminated out of 25 trials

Success Rate

86.4%

-0.1% vs benchmark

Late-Stage Pipeline

28%

7 trials in Phase 3/4

Results Transparency

26%

5 of 19 completed with results

Key Signals

5 with results86% success

Data Visualizations

Phase Distribution

23Total
Not Applicable (12)
P 1 (2)
P 2 (2)
P 3 (4)
P 4 (3)

Trial Status

Completed19
Terminated3
Active Not Recruiting1
Suspended1
Unknown1

Trial Success Rate

86.4%

Benchmark: 86.5%

Based on 19 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT03423979Phase 2Completed

Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter

NCT05768776Active Not RecruitingPrimary

Outpatient Holmium LASER Enucleation of the Prostate: Benefit of MOSES(TM) 2.0 Technology

NCT05082142Phase 4Completed

Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

NCT05308017Not ApplicableCompletedPrimary

Wolf 24 F vs. Storz 28 F Laser Sheath Size for HoLEP

NCT04781049Not ApplicableCompleted

Transperineal Laser Ablation vs Transurethral Resection for Benign Prostatic Obstruction: A Randomized Clinical Trial

NCT04398420Not ApplicableTerminatedPrimary

Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP

NCT00427219Phase 2CompletedPrimary

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

NCT02401581Not ApplicableCompletedPrimary

Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours

NCT02676544Phase 1TerminatedPrimary

Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)

NCT02533687Not ApplicableSuspendedPrimary

Comparison of Different Energy Sources During TUR-P

NCT03630926Unknown

Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.

NCT02051036Not ApplicableCompleted

Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study

NCT02509975Not ApplicableCompleted

Safety and Efficacy of OCL 503 in Prostate Artery Embolization

NCT00449150Phase 3TerminatedPrimary

Cetrorelix (CET) Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00634608Not ApplicableCompleted

Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow

NCT02429219Not ApplicableCompletedPrimary

Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate

NCT01177436Not ApplicableCompleted

Prostate Cancer Antigen 3 (PCA-3) Gene Project

NCT01342562Not ApplicableCompletedPrimary

The Effects of Intrathecal Dexmedetomidine on Spinal Anesthesia Using Diluted Low-Dose Bupivacaine for Transurethral Resection of Prostate in Elderly

NCT00771394Phase 4Completed

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia

NCT00382356Not ApplicableCompletedPrimary

Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)

Scroll to load more

Research Network

Activity Timeline